1-(苄氧基)甲基-5-甲酰基-4-碘咪唑 | 134420-45-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(苄氧基)甲基-5-甲酰基-4-碘咪唑
• 英文名称: 1-(benzyloxy)methyl-5-formyl-4-iodoimidazole
• 英文别名: 1-((Benzyloxy)methyl)-4-iodo-1H-imidazole-5-carbaldehyde；5-iodo-3-(phenylmethoxymethyl)imidazole-4-carbaldehyde
• CAS: 134420-45-4
• 化学式: C₁₂H₁₁IN₂O₂
• 分子量: 342.136
• InChiKey: GEKIKODUWFWHEG-UHFFFAOYSA-N

物化性质

• 熔点：
  43-45 °C
• 沸点：
  477.0±45.0 °C(Predicted)
• 密度：
  1.66±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(苄氧基)甲基-5-甲酰基-4-碘咪唑 在 吡啶 、 正丁基锂 、 重水 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 正己烷 、 苯 为溶剂， 反应 11.25h， 生成 2-deuterio-5-(1,3-dioxolan-2-yl)-1-(phenylmethoxymethyl)imidazole
  参考文献：
  名称：

  Regioselective formation of imidazol-2-yllithium, imidazol-4-yllithium, and imidazol-5-yllithium species

  摘要：

  Representative imidazol-2-yllithium, imidazol-4-yllithium, and imidazol-5-yllithium species have been prepared via halogen-metal exchange, and the propensity of the latter two to undergo isomerization and quench by electrophilic reagents has been studied. The C2-unsubstituted imidazol-5-yllithium species 3 is generated within 10 min at -78-degrees-C from 1-[(benzyloxy)methyl]-4,5-diiodoimidazole (1b) and affords the C5-formyl product 4 upon reaction with DMF, but gives the isomeric C2-formyl product 6 if allowed to equilibrate to the imidazol-2-yllithium species 5 for an additional 35 min at -78-degrees-C before quench. The less reactive electrophile diethyl carbonate is unable to trap 3 and instead reacts with 5 to afford tris[1-[(benzyloxy)methyl]-4-iodo-2-imidazolyl]carbinol (7). In contrast, 1-[(benzyloxy)methyl]-4-iodoimidazole-5-carboxaldehyde ethylene acetal (10) metalates to give the C2-unsubstituted imidazol-4-yllithium species 13, which undergoes a very rapid conversion to its imidazol-2-yllithium isomer 14, even at -100-degrees-C, giving the 2,5-dicarboxaldehyde 5-ethylene acetal 16 or the 2-deuterio-5-carboxaldehyde ethylene acetal 15 upon quench with DMF or D2O, respectively. Thus, in the presence of C2 unsubstitution, C5 functionalization could be accomplished when the electrophile was sufficiently reactive, while C4 functionalization could not. Short- and long-range H-1-C-13 heteronuclear (Hector) 2D NMR spectroscopic analyses were instrumental in the structural assignments of key compounds.

  DOI：

  10.1021/jo00013a042
• 作为产物：
  描述：

  N-甲基-N-(2-吡啶基)甲酰胺 、 1-benzyloxymethyl-4,5-diiodo-1H-imidazole 在 乙基溴化镁 作用下， 生成 1-(苄氧基)甲基-5-甲酰基-4-碘咪唑
  参考文献：
  名称：

  Polyfunctionalisation of imidazole via sequential imidazolyl anion formation

  摘要：

  A method for achieving the sequential functionalisation of the imidazole ring in the order C-5-->C-4-->C-2 is described. The chemistry proceeds via the regioselective formation of positionally stable imidazolyl anions which are reacted with electrophiles (aldehydes, alkyl halides, azides, formamides, isocyanates) to afford substituted imidazoles in 31-90% yield. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)00939-3

文献信息

• Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor α (TNF-α) Production:  Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3-carbonitriles
  作者：Neal Green、Yonghan Hu、Kristin Janz、Huan-Qiu Li、Neelu Kaila、Satenig Guler、Jennifer Thomason、Diane Joseph-McCarthy、Steve Y. Tam、Rajeev Hotchandani、Junjun Wu、Adrian Huang、Qin Wang、Louis Leung、Jefferey Pelker、Suzana Marusic、Sang Hsu、Jean-Baptiste Telliez、J. Perry Hall、John W. Cuozzo、Lih-Ling Lin

  DOI：10.1021/jm070436q

  日期：2007.9.1

  involved in diseases such as rheumatoid arthritis. Initial 4-anilino-6-aminoquinoline-3-carbonitrile leads showed poor selectivity for Tpl2 over epidermal growth factor receptor (EGFR) kinase. Using molecular modeling and crystallographic data of the EGFR kinase domain with and without an EGFR kinase-specific 4-anilinoquinazoline inhibitor (erlotinib, Tarceva), we hypothesized that we could diminish the

  肿瘤进展基因座2（Tpl2）（Cot / MAP3K8）是MAP3K家族中位于MEK上游的丝氨酸/苏氨酸激酶。最近使用Tpl2敲除小鼠的研究表明Tpl2在脂多糖（LPS）诱导的肿瘤坏死因子α（TNF-alpha）和其他与风湿性关节炎等疾病有关的促炎细胞因子的产生中具有重要作用。最初的4-苯胺基-6-氨基喹啉-3-甲腈导线显示出对Tpl2的选择性较表皮生长因子受体（EGFR）激酶差。使用和不使用EGFR激酶特异性4-苯胺基喹唑啉抑制剂（erlotinib，Tarceva）的EGFR激酶结构域的分子模型和晶体学数据，我们假设我们可以通过在C-8位置进行取代来减少对EGFR激酶的抑制作用4-苯胺基-6-氨基喹啉-3-腈引线。由适当的2-取代的4-硝基苯胺制备8-取代的4-苯胺基-6-氨基喹啉-3-甲腈。对C-6和C-8位置的修饰导致鉴定了对LPS刺激的大鼠和人类血液中TNF-α释放抑制作用增强的
• 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same
  申请人：Green Jeffrey Neal

  公开号：US20060264460A1

  公开（公告）日：2006-11-23

  The present invention provides compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective amount of a compound of formula (I) to the mammal.

  本发明提供了如下式（I）的化合物及其药用可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、m和n的定义如本文所述。该发明还提供了制备如式（I）化合物的方法，以及治疗炎症性疾病（如类风湿性关节炎）的方法，包括向哺乳动物施用如式（I）化合物的治疗有效量。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• 5-Substituted Imidazole-4-acetic Acid Analogues:  Synthesis, Modeling, and Pharmacological Characterization of a Series of Novel γ-Aminobutyric Acid_C Receptor Agonists
  作者：Christian Madsen、Anders A. Jensen、Tommy Liljefors、Uffe Kristiansen、Birgitte Nielsen、Camilla P. Hansen、Mogens Larsen、Bjarke Ebert、Benny Bang-Andersen、Povl Krogsgaard-Larsen、Bente Frølund

  DOI：10.1021/jm070447j

  日期：2007.8.1

  A series of ring-substituted analogues of imidazole-4-acetic acid (IAA, 4), a partial agonist at both GABA(A) and GABA(C) receptors (GABA = gamma-aminobutyric acid), have been synthesized. The synthesized compounds 8a-1 have been evaluated as ligands for the alpha(1)beta(2)gamma(2S) GABA(A) receptors and the rho(1) GABA(C) receptors using the FLIPR membrane potential (FMP) assay and by electrophysiology techniques. None of the tested compounds displayed activity at the GABA(A) receptors at concentrations up to 1000 mu M. However, the 5-Me, 5-Ph, 5-p-Me-Ph, and 5-p-F-Ph IAA analogues, 8a,c,f,g, displayed full agonist activities at the rho(1) receptors in the FMP assay (EC50 in the range 22-420 mu M). Ligand-protein docking identified the Thr129 in the alpha(1) subunit and the corresponding Ser168 residue in rho(1) as determinants of the selectivity displayed by the 5-substituted IAA analogues. The fact that GABA, 4, and 8a displayed decreased agonist potencies at a rho(1)Ser168Thr mutant compared to the WT rho(1) receptor strongly supported this hypothesis. However, in contrast to GABA and 4, which exhibited increased agonist potencies at a alpha(1)(Thr129Ser)beta(2)gamma(2) mutant compared to WT GABA(A) receptor, the data obtained for 8a at the WT and mutant receptors were nonconclusive.
• Multifunctionalization of imidazole via sequential halogen-metal exchange: a new route to purine-ring analogs
  作者：Michael P. Groziak、Lulin Wei

  DOI：10.1021/jo00040a011

  日期：1992.7

  A new method for the synthesis of purine-ring analogs based upon the sequential halogen-metal exchange functionalization of 1-[(benzyloxy)methyl]-2,4,5-triiodoimidazole (1) has been developed and is illustrated by the synthesis of (1H)-imidazo[4,5-d]pyridazin-4(5H)-one (2-aza-3-deazahypoxanthine, 8). Treatment of 1 with BuLi followed by quench with PhSSPh afforded the 2-(phenylthio) derivative, which upon treatment with BuLi followed by quench with DMF gave the 5-carboxaldehyde. This aldehyde was converted into its ethylene acetal, which was treated with BuLi followed by quench with ClCO2CH3 to afford a 4-(methoxycarbonyl)imidazole. Removal of the phenylthio group with Al(Hg) and the (benzyloxy)methyl and ethylene acetal protecting groups concomitantly with 3 M HCl afforded methyl 5(4)-formylimidazole-4(5)-carboxylate, which underwent cyclo-condensation with ethanolic NH2NH2 to give target 8. This synthetic approach was found amenable to modification by efficient ''one-pot'' multistep transformations. Thus, treatment of 1 with (a) BuLi, (b) (CH3)3SiCl, (c) BuLi, (d) (CH3)2NN(CH3)CHO, (e) BuLi, and (f) (CH3OCO)2O afforded the N-protected 4-(methoxycarbonyl)-imidazole-5-carboxaldehyde (13) in 25% yield directly from 1. Imidazole 13 was then elaborated to 8 in two steps. 1-Formyl-1,2,2-trimethylhydrazine is a recommended replacement for DMF as a tandem formylating/ortho-metalation directing agent.

表征谱图